Menu
Baiya Phytopharm’s plant-based technology is a cutting-edge solution that is quick, simple, and scalable, aiming to replace biotech fermenters with plants.
The platform has the flexibility to produce biopharmaceutical products of interest within weeks rather than months or years, resulting in a faster process and lower cost of research and development for products, such as cosmetic raw materials, diagnostic test kit materials, and therapeutics for cancer and infectious diseases. We have been scaling up our platform from scratch to hatch within our tiny laboratory since its founding in 2018. Currently, we have a cGMP facility in Bangkok, Thailand to produce clinical materials of plant-produced protein and can produce up to 5 million doses of COVID-19 vaccine per month.
Our flagship product is a COVID-19 vaccine, which is the first to be locally developed and manufactured in Thailand.
We have developed our first-generation plant-based COVID-19 vaccine, Baiya-SARS-CoV-2-Vax 1, which contains a recombinant RBD protein of the SARS-CoV-2 virus. In July 2021, our vaccine was the first to test in human trials for a plant-produced COVID-19 vaccine in Asia. With the evolution of the pandemic, the second candidate, Baiya-SARS-CoV-2-Vax 2, was developed and modelled after the prototype (Wuhan) SARS-CoV-2 RBD antigen. The preclinical study demonstrated a high protective efficacy and an improvement of the immune response against SARS-CoV-2 and its variants, compared to our first-generation vaccine. This First-in-Human clinical trial of Baiya SARS-CoV-2-Vax 2 began in March 2022 to evaluate the vaccine’s safety when administered to healthy adults. After promising results, the trial has been recommended to continue. A second round of testing is currently underway.
Our team combines deep technological expertise in plant biotech, pharmaceutical production, and clinical development to create pharmaceutical candidates for the highly unmet medical needs of the Asia-Pacific region. We have generated a broad proprietary portfolio of candidates, including monoclonal antibodies for cancer and infectious diseases and new vaccines for neglected tropical diseases.
